Scares data exists concerning the prevalence of chronic liver diseases in people with psychiatric disorders. There are still many barriers to screening and linkage to care for patients having somatic illness. Moreover follow-up of these patients may be difficult because of poor access to care, sometimes marginalization, and insufficient compliance with health programs. The aim of this study is to asses acceptability of of advanced chronic liver disease screening by transient elstography (Fibroscan ®) in patients hospitalised in a psychiatric unit.
Scares data exists concerning the prevalence of chronic liver diseases in people with psychiatric disorders. There are still many barriers to screening and linkage to care for patients having somatic illness. Moreover follow-up of these patients may be difficult because of poor access to care, sometimes marginalization, and insufficient compliance with health programs. Transient elastography is a useful tool validated for early diagnosis advanced chronic liver disease.It is non-invasive, fast, and gives immediate results. The aim of this study is to assess acceptability of of advanced chronic liver disease screening by transient elstography (Fibroscan ®) in patients hospitalised in psychiatric unit. Moreover, we will estimate de prevalence of advanced chronic liver diseases according to specific causes in psychiatry unit We hypothesize that the fact of offering psichiatric patents a non-invasive analysis of hepatic fibrosis will improve the detection of serious liver diseases and linkage to care.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
PREVENTION
Masking
NONE
Enrollment
180
A Fibroscan will be performed and the result will be given to the patient. A follow-up will be organized in the event of a diagnosis of severe fibrosis. If the serologies for hepatitis B and C cannont be recovered, patient will be able to benfit from a rapid diagnostic orientation test (TROD) (minimally invasive capillary venous sampling at the fingertip) for these 2 serologies.
Montpellier University Hospital
Montpellier, France
acceptability of non invasive assessement of liver fibrosis by Fibroscan in psychiatric patients
Number of patient who have agreed to do fibroscan screening among patient to whom it was offered.
Time frame: At Inclusion
Prevalence of advanced liver disease in psychiatric patients
Number of patient who are diagnosed with advanced liver disease among patient to whom it was offered.
Time frame: At inclusion
prevalence of excessive alcohol or drug consumption in psychiatric patients
Number of patient with excessive alcohol/drug consumption
Time frame: At inclusion
prevalence of passed or active drug consumption (intraveinous, inhaled or sniffed) in psychiatric patients
Number of patient with excessive alcohol/drug consumption
Time frame: At Inclusion
prevalence of viral hepatitis in psychiatric patients
Number of patient diagnosed with viral hepatitis B, D, C
Time frame: At Inclusion
correlation between advanced chronic liver diseases and risk factors for liver diseases in psychiatric patients
Number of patients with advanced chronic liver disease among those having risk factors for chronic liver disease
Time frame: 1 to 3 month after inclusion
assessment of referral to medical care when advanced fibrosis was diagnosed, regardless of its etiology
Number of patients that have actually came to their medical appoint after advanced fibrosis diagnosis
Time frame: 1 to 3 month after inclusion
reason for refusal of non invasive evaluation of chronic liver disease
rate of reasons of refusal according to reason of hospitalization, sector, duration of hospitalization, time spend in study explaination, patient reflection time
Time frame: At Inclusion
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.